Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Core Points - The U.S. FDA has approved Phathom Pharmaceuticals' Citizen Petition, recognizing a 10-year exclusivity period for VOQUEZNA (vonoprazan) tablets, extending through May 3, 2032 [1] Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [2] - The company has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), marketed as VOQUEZNA for various gastrointestinal conditions [2] Product Information - VOQUEZNA is indicated for the relief of heartburn associated with Non-Erosive GERD, healing and maintenance of Erosive GERD, and treatment of H. pylori infection in adults [2]